{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T23:03:08Z","timestamp":1795129388413,"version":"4.10.3"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T00:00:00Z","timestamp":1675987200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T00:00:00Z","timestamp":1675987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The anticipation of progression of Alzheimer\u2019s disease (AD) is crucial for evaluations of secondary prevention measures thought to modify the disease trajectory. However, it is difficult to forecast the natural progression of AD, notably because several functions decline at different ages and different rates in different patients. We evaluate here AD Course Map, a statistical model predicting the progression of neuropsychological assessments and imaging biomarkers for a patient from current medical and radiological data at early disease stages. We tested the method on more than 96,000 cases, with a pool of more than 4,600 patients from four continents. We measured the accuracy of the method for selecting participants displaying a progression of clinical endpoints during a hypothetical trial. We show that enriching the population with the predicted progressors decreases the required sample size by 38% to 50%, depending on trial duration, outcome, and targeted disease stage, from asymptomatic individuals at risk of AD to subjects with early and mild AD. We show that the method introduces no biases regarding sex or geographic locations and is robust to missing data. It performs best at the earliest stages of disease and is therefore highly suitable for use in prevention trials.<\/jats:p>","DOI":"10.1038\/s41467-022-35712-5","type":"journal-article","created":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T16:16:34Z","timestamp":1676045794000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["Forecasting individual progression trajectories in Alzheimer\u2019s disease"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9971-4000","authenticated-orcid":false,"given":"Etienne","family":"Maheux","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Koval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliette","family":"Ortholand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Birkenbihl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0818-7685","authenticated-orcid":false,"given":"Damiano","family":"Archetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Bouteloup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Epelbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2442-4476","authenticated-orcid":false,"given":"Carole","family":"Dufouil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9012-6720","authenticated-orcid":false,"given":"Martin","family":"Hofmann-Apitius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9450-6920","authenticated-orcid":false,"given":"Stanley","family":"Durrleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,10]]},"reference":[{"key":"35712_CR1","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.trci.2018.04.008","volume":"4","author":"J Cummings","year":"2018","unstructured":"Cummings, J., Reiber, C. & Kumar, P. The price of progress: funding and financing Alzheimer\u2019s disease drug development. Alzheimers Dement. Transl. Res. Clin. Interv. 4, 330\u2013343 (2018).","journal-title":"Alzheimers Dement. Transl. Res. Clin. Interv."},{"key":"35712_CR2","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/S1474-4422(19)30480-6","volume":"19","author":"L Schneider","year":"2020","unstructured":"Schneider, L. A resurrection of aducanumab for Alzheimer\u2019s disease. Lancet Neurol. 19, 111\u2013112 (2020).","journal-title":"Lancet Neurol."},{"key":"35712_CR3","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13195-020-00663-w","volume":"12","author":"M Tolar","year":"2020","unstructured":"Tolar, M., Abushakra, S., Hey, J. A., Porsteinsson, A. & Sabbagh, M. Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer\u2019s disease with potential for near term approval. Alzheimers Res. Ther. 12, 95 (2020).","journal-title":"Alzheimers Res. Ther."},{"key":"35712_CR4","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13195-019-0529-5","volume":"11","author":"J Cummings","year":"2019","unstructured":"Cummings, J., Feldman, H. H. & Scheltens, P. The \u201crights\u201d of precision drug development for Alzheimer\u2019s disease. Alzheimers Res. Ther. 11, 76 (2019).","journal-title":"Alzheimers Res. Ther."},{"key":"35712_CR5","doi-asserted-by":"publisher","first-page":"e2673","DOI":"10.1212\/WNL.0000000000012022","volume":"96","author":"RJ Jutten","year":"2021","unstructured":"Jutten, R. J. et al. Finding treatment effects in Alzheimer trials in the face of disease progression heterogeneity. Neurology 96, e2673\u2013e2684 (2021).","journal-title":"Neurology"},{"key":"35712_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-87434-1","volume":"11","author":"I Koval","year":"2021","unstructured":"Koval, I. et al. AD course map charts Alzheimer\u2019s disease progression. Sci. Rep. 11, 8020 (2021).","journal-title":"Sci. Rep."},{"key":"35712_CR7","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s40708-019-0099-0","volume":"6","author":"S Iddi","year":"2019","unstructured":"Iddi, S. et al. Predicting the course of Alzheimer\u2019s progression. Brain Inform. 6, 6 (2019).","journal-title":"Brain Inform."},{"key":"35712_CR8","first-page":"205","volume":"11","author":"M Bilgel","year":"2019","unstructured":"Bilgel, M. & Jedynak, B. M. Predicting time to dementia using a quantitative template of disease progression. Alzheimers Dement. Diagn. Assess. Dis. Monit. 11, 205\u2013215 (2019).","journal-title":"Alzheimers Dement. Diagn. Assess. Dis. Monit."},{"key":"35712_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05892-0","volume":"9","author":"AL Young","year":"2018","unstructured":"Young, A. L. et al. Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with Subtype and Stage Inference. Nat. Commun. 9, 4273 (2018).","journal-title":"Nat. Commun."},{"key":"35712_CR10","doi-asserted-by":"publisher","first-page":"101954","DOI":"10.1016\/j.nicl.2019.101954","volume":"24","author":"D Archetti","year":"2019","unstructured":"Archetti, D. et al. Multi-study validation of data-driven disease progression models to characterize evolution of biomarkers in Alzheimer\u2019s disease. NeuroImage Clin. 24, 101954 (2019).","journal-title":"NeuroImage Clin."},{"key":"35712_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-29433-3","volume":"8","author":"S Khanna","year":"2018","unstructured":"Khanna, S. et al. Using Multi-Scale Genetic, Neuroimaging and Clinical Data for Predicting Alzheimer\u2019s Disease and Reconstruction of Relevant Biological Mechanisms. Sci. Rep. 8, 11173 (2018).","journal-title":"Sci. Rep."},{"key":"35712_CR12","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.neuroimage.2017.08.059","volume":"190","author":"M Lorenzi","year":"2019","unstructured":"Lorenzi, M., Filippone, M., Frisoni, G. B., Alexander, D. C. & Ourselin, S. Probabilistic disease progression modeling to characterize diagnostic uncertainty: application to staging and prediction in Alzheimer\u2019s disease. NeuroImage 190, 56\u201368 (2019).","journal-title":"NeuroImage"},{"key":"35712_CR13","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/S1474-4422(19)30283-2","volume":"18","author":"IS van Maurik","year":"2019","unstructured":"van Maurik, I. S. et al. Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study. Lancet Neurol. 18, 1034\u20131044 (2019).","journal-title":"Lancet Neurol."},{"key":"35712_CR14","doi-asserted-by":"publisher","unstructured":"Birkenbihl, C., Salimi, Y., Fr\u00f6hlich, H., Japanese Alzheimer\u2019s Disease Neuroimaging Initiative, & Alzheimer\u2019s Disease Neuroimaging Initiative. Unraveling the heterogeneity in Alzheimer\u2019s disease progression across multiple cohorts and the implications for data-driven disease modeling. Alzheimers Dement. J. Alzheimers Assoc. https:\/\/doi.org\/10.1002\/alz.12387 (2021).","DOI":"10.1002\/alz.12387"},{"key":"35712_CR15","doi-asserted-by":"publisher","unstructured":"Oxtoby, N. P. et al. Targeted screening for Alzheimer\u2019s disease clinical trials using data-driven disease progression models. medRxiv https:\/\/doi.org\/10.1101\/2021.01.29.21250773 (2021).","DOI":"10.1101\/2021.01.29.21250773"},{"key":"35712_CR16","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1002\/acn3.192","volume":"2","author":"PS Insel","year":"2015","unstructured":"Insel, P. S. et al. Biomarkers and cognitive endpoints to optimize trials in Alzheimer\u2019s disease. Ann. Clin. Transl. Neurol. 2, 534\u2013547 (2015).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"35712_CR17","doi-asserted-by":"publisher","unstructured":"K\u00fchnel, L. et al. Personalized prediction of progression in pre-dementia patients based on individual biomarker profile: a development and validation study. Alzheimers Dement. J. Alzheimers Assoc. https:\/\/doi.org\/10.1002\/alz.12363 (2021).","DOI":"10.1002\/alz.12363"},{"key":"35712_CR18","unstructured":"Center for Drug Evaluation and Research & Center for Biologics Evaluation and Research. Enrichment Strategies for Clinical Trials to Support Approval of Human Drugs and Biological Products. U.S. Food and Drug Administration https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/enrichment-strategies-clinical-trials-support-approval-human-drugs-and-biological-products (2019)."},{"key":"35712_CR19","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.trci.2019.09.010","volume":"5","author":"DK Burns","year":"2019","unstructured":"Burns, D. K. et al. The TOMMORROW study: design of an Alzheimer\u2019s disease delay\u2010of\u2010onset clinical trial. Alzheimers Dement. Transl. Res. Clin. Interv. 5, 661\u2013670 (2019).","journal-title":"Alzheimers Dement. Transl. Res. Clin. Interv."},{"key":"35712_CR20","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/S1474-4422(21)00043-0","volume":"20","author":"DK Burns","year":"2021","unstructured":"Burns, D. K. et al. Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer\u2019s disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 20, 537\u2013547 (2021).","journal-title":"Lancet Neurol."},{"key":"35712_CR21","unstructured":"Schiratti, J.-B., Allassonniere, S., Colliot, O. & Durrleman, S. Learning spatiotemporal trajectories from manifold-valued longitudinal data. in Neural Information Processing Systems (2015)."},{"key":"35712_CR22","first-page":"1","volume":"18","author":"J-B Schiratti","year":"2017","unstructured":"Schiratti, J.-B., Allassonni\u00e8re, S., Colliot, O. & Durrleman, S. A bayesian mixed-effects model to learn trajectories of changes from repeated manifold-valued observations. J. Mach. Learn. Res. 18, 1\u201333 (2017).","journal-title":"J. Mach. Learn. Res."},{"key":"35712_CR23","doi-asserted-by":"crossref","unstructured":"Marinescu, R. V. et al. TADPOLE challenge: accurate Alzheimer\u2019s disease prediction through crowdsourced forecasting of future data. in Predictive Intelligence in Medicine (eds. Rekik, I., Adeli, E. & Park, S. H.) vol. 11843, 1\u201310 (Springer International Publishing, 2019).","DOI":"10.1007\/978-3-030-32281-6_1"},{"key":"35712_CR24","doi-asserted-by":"publisher","first-page":"117203","DOI":"10.1016\/j.neuroimage.2020.117203","volume":"222","author":"M Nguyen","year":"2020","unstructured":"Nguyen, M. et al. Predicting Alzheimer\u2019s disease progression using deep recurrent neural networks. NeuroImage 222, 117203 (2020).","journal-title":"NeuroImage"},{"key":"35712_CR25","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jalz.2005.06.003","volume":"1","author":"SG Mueller","year":"2005","unstructured":"Mueller, S. G. et al. Ways toward an early diagnosis in Alzheimer\u2019s disease: the Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI). Alzheimers Dement. J. Alzheimers Assoc. 1, 55\u201366 (2005).","journal-title":"Alzheimers Dement. J. Alzheimers Assoc."},{"key":"35712_CR26","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1002\/jmri.21049","volume":"27","author":"CR Jack","year":"2008","unstructured":"Jack, C. R. et al. The Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI): MRI methods. J. Magn. Reson. Imaging JMRI 27, 685\u2013691 (2008).","journal-title":"J. Magn. Reson. Imaging JMRI"},{"key":"35712_CR27","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1212\/WNL.0b013e3181cb3e25","volume":"74","author":"RC Petersen","year":"2010","unstructured":"Petersen, R. C. et al. Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology 74, 201\u2013209 (2010).","journal-title":"Neurology"},{"key":"35712_CR28","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.jalz.2010.03.004","volume":"6","author":"CR Jack","year":"2010","unstructured":"Jack, C. R. et al. Update on the MRI core of the Alzheimer\u2019s disease neuroimaging initiative. Alzheimers Dement. J. Alzheimers Assoc. 6, 212\u2013220 (2010).","journal-title":"Alzheimers Dement. J. Alzheimers Assoc."},{"key":"35712_CR29","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.jalz.2015.05.004","volume":"11","author":"LA Beckett","year":"2015","unstructured":"Beckett, L. A. et al. The Alzheimer\u2019s disease neuroimaging initiative 2: increasing the length, breadth, and depth of our understanding. Alzheimers Dement. J. Alzheimers Assoc. 11, 823\u2013831 (2015).","journal-title":"Alzheimers Dement. J. Alzheimers Assoc."},{"key":"35712_CR30","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.jalz.2015.05.002","volume":"11","author":"CR Jack","year":"2015","unstructured":"Jack, C. R. et al. Magnetic resonance imaging in Alzheimer\u2019s Disease neuroimaging initiative 2. Alzheimers Dement. 11, 740\u2013756 (2015).","journal-title":"Alzheimers Dement."},{"key":"35712_CR31","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.jalz.2016.10.006","volume":"13","author":"MW Weiner","year":"2017","unstructured":"Weiner, M. W. et al. The Alzheimer\u2019s Disease Neuroimaging Initiative 3: continued innovation for clinical trial improvement. Alzheimers Dement. 13, 561\u2013571 (2017).","journal-title":"Alzheimers Dement."},{"key":"35712_CR32","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1017\/S1041610209009405","volume":"21","author":"KA Ellis","year":"2009","unstructured":"Ellis, K. A. et al. The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer\u2019s disease. Int. Psychogeriatr. 21, 672\u2013687 (2009).","journal-title":"Int. Psychogeriatr."},{"key":"35712_CR33","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.neuropsychologia.2015.06.008","volume":"75","author":"MA Albrecht","year":"2015","unstructured":"Albrecht, M. A. et al. Longitudinal cognitive decline in the AIBL cohort: the role of APOE \u03b54 status. Neuropsychologia 75, 411\u2013419 (2015).","journal-title":"Neuropsychologia"},{"key":"35712_CR34","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.jalz.2010.03.011","volume":"6","author":"T Iwatsubo","year":"2010","unstructured":"Iwatsubo, T. Japanese Alzheimer\u2019s disease neuroimaging initiative: present status and future. Alzheimers Dement. 6, 297\u2013299 (2010).","journal-title":"Alzheimers Dement."},{"key":"35712_CR35","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1016\/j.jalz.2018.03.009","volume":"14","author":"T Iwatsubo","year":"2018","unstructured":"Iwatsubo, T. et al. Japanese and North American Alzheimer\u2019s Disease Neuroimaging Initiative studies: harmonization for international trials. Alzheimers Dement. 14, 1077\u20131087 (2018).","journal-title":"Alzheimers Dement."},{"key":"35712_CR36","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1111\/joim.12482","volume":"279","author":"S Galluzzi","year":"2016","unstructured":"Galluzzi, S. et al. Clinical and biomarker profiling of prodromal Alzheimer\u2019s disease in workpackage 5 of the Innovative Medicines Initiative PharmaCog project: a \u2018European ADNI study\u2019. J. Intern. Med. 279, 576\u2013591 (2016).","journal-title":"J. Intern. Med."},{"key":"35712_CR37","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3233\/JAD-180321","volume":"69","author":"D Albani","year":"2019","unstructured":"Albani, D. et al. Plasma A\u03b242 as a biomarker of prodromal alzheimer\u2019s disease progression in patients with amnestic mild cognitive impairment: evidence from the PharmaCog\/E-ADNI Study. J. Alzheimers Dis. JAD 69, 37\u201348 (2019).","journal-title":"J. Alzheimers Dis. JAD"},{"key":"35712_CR38","doi-asserted-by":"crossref","unstructured":"Dufouil, C. et al. Cognitive and imaging markers in non-demented subjects attending a memory clinic: study design and baseline findings of the MEMENTO cohort. Alzheimers Res. Ther. 9, 67 (2017).","DOI":"10.1186\/s13195-017-0288-0"},{"key":"35712_CR39","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein, M. F., Folstein, S. E. & McHugh, P. R. \u201cMini-mental state\u201d: a practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12, 189\u2013198 (1975).","journal-title":"J. Psychiatr. Res."},{"key":"35712_CR40","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1176\/ajp.141.11.1356","volume":"141","author":"WG Rosen","year":"1984","unstructured":"Rosen, W. G., Mohs, R. C. & Davis, K. L. A new rating scale for Alzheimer\u2019s disease. Am. J. Psychiatry 141, 1356\u20131364 (1984).","journal-title":"Am. J. Psychiatry"},{"key":"35712_CR41","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1001\/archneur.65.8.1091","volume":"65","author":"SE O\u2019Bryant","year":"2008","unstructured":"O\u2019Bryant, S. E. et al. Staging dementia using clinical dementia rating scale sum of boxes scores. Arch. Neurol. 65, 1091\u20131095 (2008).","journal-title":"Arch. Neurol."},{"key":"35712_CR42","doi-asserted-by":"publisher","unstructured":"Hedges, E. P. et al. Reliability of structural MRI measurements: the effects of scan session, head tilt, inter-scan interval, acquisition sequence, FreeSurfer version and processing stream. NeuroImage https:\/\/doi.org\/10.1016\/j.neuroimage.2021.118751 (2021).","DOI":"10.1016\/j.neuroimage.2021.118751"},{"key":"35712_CR43","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.jalz.2014.02.004","volume":"11","author":"K Blennow","year":"2015","unstructured":"Blennow, K. et al. Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer\u2019s disease. Alzheimers Dement. 11, 58\u201369 (2015).","journal-title":"Alzheimers Dement."},{"key":"35712_CR44","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/s43587-020-00003-5","volume":"1","author":"NC Cullen","year":"2021","unstructured":"Cullen, N. C. et al. Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations. Nat. Aging 1, 114\u2013123 (2021).","journal-title":"Nat. Aging"},{"key":"35712_CR45","doi-asserted-by":"publisher","unstructured":"Chen, R. et al. Developing Measures of Cognitive Impairment in the Real World from Consumer-Grade Multimodal Sensor Streams. in Proceedings of the 25th ACM SIGKDD International Conference on Knowledge Discovery & Data Mining 2145\u20132155 (Association for Computing Machinery, 2019). https:\/\/doi.org\/10.1145\/3292500.3330690.","DOI":"10.1145\/3292500.3330690"},{"key":"35712_CR46","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1097\/00002093-199700112-00003","volume":"11","author":"RC Mohs","year":"1997","unstructured":"Mohs, R. C. et al. Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer\u2019s Disease Assessment Scale that broaden its scope. The Alzheimer\u2019s Disease Cooperative Study. Alzheimer Dis. Assoc. Disord. 11, S13\u2013S21 (1997).","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"35712_CR47","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1192\/bjp.140.6.566","volume":"140","author":"CP Hughes","year":"1982","unstructured":"Hughes, C. P., Berg, L., Danziger, W. L., Coben, L. A. & Martin, R. L. A new clinical scale for the staging of dementia. Br. J. Psychiatry 140, 566\u2013572 (1982).","journal-title":"Br. J. Psychiatry"},{"key":"35712_CR48","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.neuroimage.2005.09.046","volume":"30","author":"J Jovicich","year":"2006","unstructured":"Jovicich, J. et al. Reliability in multi-site structural MRI studies: effects of gradient non-linearity correction on phantom and human data. NeuroImage 30, 436\u2013443 (2006).","journal-title":"NeuroImage"},{"key":"35712_CR49","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1109\/42.668698","volume":"17","author":"JG Sled","year":"1998","unstructured":"Sled, J. G., Zijdenbos, A. P. & Evans, A. C. A nonparametric method for automatic correction of intensity nonuniformity in MRI data. IEEE Trans. Med. Imaging 17, 87\u201397 (1998).","journal-title":"IEEE Trans. Med. Imaging"},{"key":"35712_CR50","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1016\/j.neuroimage.2007.10.026","volume":"39","author":"RG Boyes","year":"2008","unstructured":"Boyes, R. G. et al. Intensity non-uniformity correction using N3 on 3-T scanners with multichannel phased array coils. NeuroImage 39, 1752\u20131762 (2008).","journal-title":"NeuroImage"},{"key":"35712_CR51","doi-asserted-by":"publisher","first-page":"653","DOI":"10.3174\/ajnr.A4228","volume":"36","author":"N Chow","year":"2015","unstructured":"Chow, N. et al. Comparing 3T and 1.5T MRI for mapping hippocampal atrophy in the Alzheimer\u2019s disease neuroimaging initiative. Am. J. Neuroradiol. 36, 653\u2013660 (2015).","journal-title":"Am. J. Neuroradiol."},{"key":"35712_CR52","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3233\/JAD-160621","volume":"56","author":"M Fujishima","year":"2017","unstructured":"Fujishima, M. et al. Sample size estimation for Alzheimer\u2019s Disease Trials from Japanese ADNI serial magnetic resonance imaging. J. Alzheimers Dis. JAD 56, 75\u201388 (2017).","journal-title":"J. Alzheimers Dis. JAD"},{"key":"35712_CR53","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s12021-016-9295-8","volume":"14","author":"G Operto","year":"2016","unstructured":"Operto, G. et al. CATI: a large distributed infrastructure for the neuroimaging of cohorts. Neuroinformatics 14, 253\u2013264 (2016).","journal-title":"Neuroinformatics"},{"key":"35712_CR54","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3389\/fninf.2021.689675","volume":"15","author":"A Routier","year":"2021","unstructured":"Routier, A. et al. Clinica: an open-source software platform for reproducible clinical neuroscience studies. Front. Neuroinformatics 15, 39 (2021).","journal-title":"Front. Neuroinformatics"},{"key":"35712_CR55","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.neuroimage.2014.01.058","volume":"92","author":"ER Mulder","year":"2014","unstructured":"Mulder, E. R. et al. Hippocampal volume change measurement: quantitative assessment of the reproducibility of expert manual outlining and the automated methods FreeSurfer and FIRST. NeuroImage 92, 169\u2013181 (2014).","journal-title":"NeuroImage"},{"key":"35712_CR56","doi-asserted-by":"publisher","first-page":"3516","DOI":"10.1002\/hbm.22859","volume":"36","author":"M Marizzoni","year":"2015","unstructured":"Marizzoni, M. et al. Longitudinal reproducibility of automatically segmented hippocampal subfields: a multisite European 3T study on healthy elderly. Hum. Brain Mapp. 36, 3516\u20133527 (2015).","journal-title":"Hum. Brain Mapp."},{"key":"35712_CR57","doi-asserted-by":"publisher","first-page":"567","DOI":"10.2967\/jnumed.114.148981","volume":"56","author":"SM Landau","year":"2015","unstructured":"Landau, S. M. et al. Measurement of longitudinal \u03b2-amyloid change with 18F-florbetapir PET and standardized uptake value ratios. J. Nucl. Med. Publ. Soc. Nucl. Med. 56, 567\u2013574 (2015).","journal-title":"J. Nucl. Med. Publ. Soc. Nucl. Med."},{"key":"35712_CR58","unstructured":"Landau, S., Murphy, A., Qie Lee, J., Ward, T. & Jagust, W. Florbetapir (AV45) processing methods. (2021). https:\/\/adni.bitbucket.io\/reference\/docs\/UCBERKELEYAV45\/UCBERKELEY_AV45_Methods_11.15.2021.pdf."},{"key":"35712_CR59","unstructured":"Landau, S., Murphy, A., Qie Lee, J., Ward, T. & Jagust, W. Florbetaben (FBB) processing methods. (2021). https:\/\/adni.bitbucket.io\/reference\/docs\/UCBERKELEYFBB\/UCBerkeley_FBB_Methods_11.15.2021.pdf."},{"key":"35712_CR60","first-page":"1-15.e1","volume":"11","author":"WE Klunk","year":"2015","unstructured":"Klunk, W. E. et al. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. J. Alzheimers Assoc. 11, 1-15.e1\u20134 (2015).","journal-title":"Alzheimers Dement. J. Alzheimers Assoc."},{"key":"35712_CR61","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s13195-021-00836-1","volume":"13","author":"SK Royse","year":"2021","unstructured":"Royse, S. K. et al. Validation of amyloid PET positivity thresholds in centiloids: a multisite PET study approach. Alzheimers Res. Ther. 13, 99 (2021).","journal-title":"Alzheimers Res. Ther."},{"key":"35712_CR62","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/BF00308809","volume":"82","author":"H Braak","year":"1991","unstructured":"Braak, H. & Braak, E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82, 239\u2013259 (1991).","journal-title":"Acta Neuropathol."},{"key":"35712_CR63","unstructured":"Landau, S., Ward, T. J., Murphy, A. & Jagust, W. Flortaucipir (AV-1451) processing methods. (2021). https:\/\/adni.bitbucket.io\/reference\/docs\/UCBERKELEYAV1451\/UCBERKELEY_AV1451_Methods_2021-01-14.pdf."},{"key":"35712_CR64","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1212\/WNL.0000000000002923","volume":"87","author":"CR Jack","year":"2016","unstructured":"Jack, C. R. et al. A\/T\/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology 87, 539\u2013547 (2016).","journal-title":"Neurology"},{"key":"35712_CR65","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack","year":"2018","unstructured":"Jack, C. R. et al. NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 14, 535\u2013562 (2018).","journal-title":"Alzheimers Dement."},{"key":"35712_CR66","doi-asserted-by":"publisher","unstructured":"Nguyen, M., Sun, N., Alexander, D. C., Feng, J. & Yeo, B. T. T. Modeling Alzheimer\u2019s disease progression using deep recurrent neural networks. in 2018 International Workshop on Pattern Recognition in Neuroimaging (PRNI) 1\u20134 https:\/\/doi.org\/10.1109\/PRNI.2018.8423955 (2018).","DOI":"10.1109\/PRNI.2018.8423955"},{"key":"35712_CR67","doi-asserted-by":"publisher","unstructured":"Inference for the Random Effects. in Linear Mixed Models for Longitudinal Data (eds. Verbeke, G. & Molenberghs, G.) 77\u201392 (Springer, 2000). https:\/\/doi.org\/10.1007\/978-0-387-22775-7_7.","DOI":"10.1007\/978-0-387-22775-7_7"},{"key":"35712_CR68","doi-asserted-by":"publisher","unstructured":"Maheux, E. Forecasting individual progression trajectories in Alzheimer\u2019s disease \u2013 software and source data. https:\/\/doi.org\/10.5281\/zenodo.7331109 (2022).","DOI":"10.5281\/zenodo.7331109"},{"key":"35712_CR69","doi-asserted-by":"publisher","unstructured":"Seabold, S. & Perktold, J. Statsmodels: econometric and statistical modeling with python. in 92\u201396 https:\/\/doi.org\/10.25080\/Majora-92bf1922-011 (2010).","DOI":"10.25080\/Majora-92bf1922-011"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-35712-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-35712-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-35712-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T11:14:42Z","timestamp":1676286882000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-35712-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,10]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["35712"],"URL":"https:\/\/doi.org\/10.1038\/s41467-022-35712-5","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,10]]},"assertion":[{"value":"14 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.E. received personal fees from Biogen, Eisai, Roche, and GE Healthcare for presentations and participation in advisory boards. S.D. is co-inventor of the patent \u201ca method for determining the temporal progression of a biological phenomenon and associated methods and devices\u201d which protects the potential uses of AD Course Map including targeting the time to administer medicine or identifying a biomarker (applicants: Inserm, CNRS, Sorbonne Universit\u00e9, Inria, Ecole Polytechnique, ICM, AP-HP, inventors: Stanley Durrleman, Jean-Baptiste Schiratti, St\u00e9phanie Allassonni\u00e8re, Olivier Colliot, international application number: PCT\/IB2016\/052699, granted in the USA (grant number 10832089), published in Europe and Japan. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"761"}}